SPC Life Sciences IPO Date, Review, Price, Allotment, Analysis

SPC Life Science date has been confirmed from October, 2023 and ended on October, 2023. Read the post to learn about SPC Life Sciences IPO GMP.

The SPC Life Sciences IPO date is undisclosed; however, the IPO is expected to go public in October 2023 and close in October 2023. SPC Life Sciences IPO will generate approximately [.] crores through an IPO that includes a fresh issue of 300 crores and an offer for sale of up to 8,938,870 equity shares at a price of 10 rupees each. The retail quota is 35%, the QIB share is 50%, and the HNI share is 15%.

Start your investing journey today. Find the latest information on Upcoming IPOs.

Key Details Of SPC Life Sciences IPO:

SPC Life Sciences GMP

The SPC Life Sciences IPO GMP Today is ₹[ ].

SPC Life Sciences GMP IPO Overview​

SPC Life Sciences will be carried out in October 2023, with the IPO date fortunately not yet exposed. The Rs.300 crore fresh issue together with up to 8,938,870 equity shares valued at Rs 10 each constitutes the offering. The estimate at which it will raise the funds from the public is Rs. [dot] crore. Retail investors get a guaranteed 35% of the allocation, while qualified institutional buyers (QIB) will take 50%, and high net worth individuals (HNI) will have 15% of it.

SPC Life Sciences of India provides manufacture of intermediates, which are key active pharmaceutical ingredients (APIs), used in production of advanced pharmaceutical compounds. These API encompass Pentoxifylline, Amiodarone HCL, Cilostazol, Trazodone, Tramadol, and Paroxetine as its constituent components or their active ingredients. The business, basically, is operating on two main wings: R&D and chemical manufacturing, with the main operation isolation being the long-chain and multi-stage multi responses.

Their innovative manufacturing of highly favorite Pharmaceutical intermediates (Pharma Intermediates) may be successfully applied in cardiovascular, cardioprotective (anti-platelet), and psychopharmacology (anti-depressive) areas. The sales of SPC Life Sciences dome in India and also globally through certain products is what sustain its prominence in the market. They stand out because of a recognized FDA-approved facility for 6-Chloro-Hexane-2-One, which helps them in designing Pharma Intermediates and work with pharmaceutical companies interested in supplies from the US FDA-compliant facilities within the respective supply chains.

SPC Life Sciences IPO Date & Price Band Details

IPO Open:	2023
IPO Close:	2023
IPO Size:	Approx ₹[.] Crores
Fresh Issue:	Approx ₹300 Crores
Offer for Sale:	Approx 8,938,870 Equity Shares
Face Value:	₹10 Per Equity Share
IPO Price Band:	₹[.] to ₹[.] Per Share
IPO Listing on:	BSE & NSE
Retail Quota:	35%
QIB Quota:	50%
NII Quota:	15%
Discount:	N/A

SPC Life Sciences IPO Market Lot

The minimum market lot for the SPC Life Sciences IPO is [.] shares, requiring an application amount of ₹[.]. Retail investors have the opportunity to apply for a maximum of 13 lots, which is equivalent to [.] shares or ₹[.] amount.

Application	Lot Size	Shares	Amount
Retail Minimum	1	–	₹-
Retail Maximum	13	–	₹-
S-HNI Minimum	14	–	₹-
B-HNI Minimum	68	–	₹-

SPC Life Sciences IPO Allotment and Listing Dates

The IPO date for SPC Life Sciences is scheduled for 2023, with the closing date set for October of the same year. The allotment for the SPC Life Sciences IPO will be completed in 2023, and the listing of the IPO is also expected to take place in the same year.

Price Band Announcement:	2023
Anchor Investors Allotment:	2023
IPO Open Date:	2023
IPO Close Date:	2023
Basis of Allotment:	2023
Refunds:	2023
Credit to Demat Account:	2023
IPO Listing Date:	2023

SPC Life Sciences Company Financial Report

Year (₹ in Crores)	Revenue	Expense	PAT
2020	₹121.10	₹106.92	₹10.38
2021	₹136.14	₹113.92	₹16.67
2022	₹146.44	₹120.56	₹19.23

SPC Life Sciences IPO Valuation – FY2022

Please review the valuation details of SPC Life Sciences IPO, including information on Earning Per Share (EPS), Price/Earning P/E Ratio, Return on Net Worth (RoNW), and Net Asset Value (NAV).

Earning Per Share (EPS):	₹4.30 per Equity Share
Price/Earning P/E Ratio:	N/A
Return on Net Worth (RoNW):	28.00%
Net Asset Value (NAV):	₹61.48 per Equity Share

Company Profile​

with some of the products having a significant market share both in India and globally. They may produce Pharma Intermediates and work with pharmaceutical companies looking for US FDA-compliant manufacturing facilities as part of their supply chain because they have a US FDA-approved facility for 6-Chloro-Hexane-2-One.

IPO Strengths

• Experienced promoters and a competent management team.
• Well-established relationships with a loyal customer base.
• Access to markets worldwide, enabling global reach.

IPO Weakness

• Heavy reliance on customers based in the United States.
• Need to adhere to multiple laws and regulations in these countries to ensure compliance.
• Competition from other players in the market.

SPC Life Sciences FAQs